April 2015 Analysis

Industry Trend Analysis - Novartis In Pole Position With Cosentyx' EU Approval For Plaque Psoriasis - APR 2015

EU approval puts Cosentyx on course to achieve blockbuster status, with US approval also anticipated early in 2015. Novartis' drug has already shown superiority over its main competition in the lucrative adult plaque psoriasis market. As many as 50% of patients are unhappy with their treatments; if Cosentyx can overcome this hurdle it will emerge as a clear winner.